Kimia Farma narrows third-quarter net loss to Rp13 billion
Operating profit rose 129.31 per cent year on year to Rp227 billion, while EBITDA increased 32.04 per cent.
Indonesia’s PT Kimia Farma (Persero) Tbk reported a net loss of Rp13 billion for the third quarter of 2026, compared with Rp234 billion a year earlier. The company said the loss had narrowed by about 94.49 per cent, with sales reaching Rp7 trillion.
Operating profit reached Rp227 billion, up 129.31 per cent from Rp99 billion in the corresponding period of 2025. EBITDA increased 32.04 per cent to Rp503 billion from Rp381 billion.
President director Djagad Prakasa Dwialam attributed the operating gains to improvements in efficiency and business effectiveness. In comments cited on 2 November 2026, he said the results indicated progress in the company’s ongoing turnaround, while stressing that its efforts extended beyond short-term financial improvements.
For the fourth quarter of 2026, Kimia Farma plans to prioritise governance changes and stronger business fundamentals. Its work will focus on internal controls, risk management, decision-making discipline and accountability.
The company also said it would continue strengthening working-capital and liquidity management, controlling costs, improving asset productivity and optimising its product portfolio. It is continuing efforts to resolve longstanding challenges in line with applicable rules and corporate governance principles, while taking account of shareholder interests and operational continuity.
